Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Diagnosed with CD-22 positive* B-cell Acute Lymphoblastic Leukemia or B-cell
             Lymphoblastic Lymphoma (Philadelphia chromosome negative) * For the purposes of this
             study, CD-22 positive is defined as at least 60% positive by flow cytometry or
             immunohistochemistry.

          4. Body mass index (BMI) < 35 (BMI = weight in kg/(height in meters)^2)

          5. Male or female, aged 18-55 years

          6. ECOG performance status of 0-2

          7. Left ventricular ejection fraction > 45% measured by echocardiogram or MUGA

          8. Either relapsed following remission after initial induction therapy or refractory to
             induction therapy

          9. Adequate organ function, including serum creatinine ≤ 1.6 mg/dL or creatinine
             clearance < 50 ml/min by Cockgroft-Gault formula, bilirubin ≤ 1.5 mg/dL (except in
             patients with Gilbert's disease), AST, ALT and alkaline phosphatase ≤ 3 x upper limit
             of normal

         10. For females of reproductive potential: negative pregnancy test

         11. For females and males of reproductive potential: agreement to use adequate
             contraception during study participation and for an additional 1 year after the end of
             study treatment

         12. Agreement to adhere to Lifestyle Considerations throughout study duration and for 1
             year following last study treatment.

        Exclusion Criteria:

          1. Requires concomitant therapeutic anticoagulation (e.g. warfarin, low molecular weight
             heparin, direct oral anticoagulant) or any medication included in the restricted
             concomitant medications

          2. Past receipt of a total of ≥ 300 mg/m^2 doxorubicin equivalents (600 mg/m^2
             daunorubicin, 60 mg/m^2 idarubicin, 75 mg/m^2 mitoxantrone)

          3. Current or past history of pancreatitis

          4. QT interval on electrocardiogram (ECG) > 0.45 by Framingham formula

          5. Known congestive heart failure

          6. Known allergy to asparaginase (only an exclusion criteria for participants enrolling
             in part 2)

          7. Presence of central nervous system (CNS) disease

          8. Pregnancy or lactation

          9. Chronic liver disease including chronic active hepatitis and/or cirrhosis

         10. Active Hepatitis B virus (HBV) by core antibody, surface antigen (HBsAg) or viral load

         11. Active Hepatitis C virus (HCV) (positive antibody test confirmed by viral load if
             antibody test is positive)

         12. Known history of infection with Human Immunodeficiency Virus (HIV)

         13. Active or uncontrolled infections

         14. Abnormal baseline hepatic ultrasound (including Dopplers)

         15. Prior allogeneic stem cell transplant

         16. Prior use of inotuzumab ozogamicin

         17. Known diagnosis of hemochromatosis with iron overload

         18. Prior CAR-T cell therapy

         19. Treatment with steroids or hydroxyurea for more than 7 days within the 2 weeks prior
             to registration

         20. Gastrointestinal tract disease causing the inability to take oral medication,
             malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior
             surgical procedures affecting absorption, uncontrolled inflammatory GI disease, or
             inability to swallow medications.

         21. Philadelphia chromosome positive B-cell ALL